Blackrock Neurotech — Entity Profile & Utah Array Legacy

Blackrock Neurotech — Entity Profile & Utah Array Legacy

Blackrock Neurotech manufactures the Utah Array, the intracortical electrode array that has been the foundation of the BrainGate clinical research program — the longest-running and most scientifically productive human BCI program in history.

Corporate Overview

Founded: 2008 (as Blackrock Microsystems, rebranded to Blackrock Neurotech) Headquarters: Salt Lake City, Utah Primary Products: Utah Array, Cerebus neural recording systems, MicroPort neural interfaces Primary Focus: Neural interface hardware for research and clinical applications Key Distinction: Longest clinical track record in intracortical BCI through BrainGate partnership

Blackrock Neurotech traces its origins to the laboratory of Richard Normann at the University of Utah, who invented the Utah Array in the late 1990s. The Utah Array — a 10x10 grid of silicon microelectrodes approximately 1.5 millimeters in length — was originally developed for neuroscience research and was subsequently adapted for human clinical use in the BrainGate program. Blackrock Microsystems was founded to commercialize the technology, later rebranding as Blackrock Neurotech to reflect its broader focus on neural interface technology.

The Utah Array

The Utah Array is a silicon microelectrode array consisting of 100 electrodes arranged in a 10x10 grid on a 4mm x 4mm silicon base. Each electrode is a tapered silicon needle approximately 1-1.5 millimeters long, with a platinum or iridium oxide tip that records electrical activity from individual neurons and small neural populations.

Manufacturing: The Utah Array is manufactured using semiconductor microfabrication techniques. A silicon wafer is etched to create an array of sharp needles, each electrically isolated from its neighbors. The tips are coated with conductive materials, and bonding pads on the base connect to external electronics through a bundle of fine wires.

Insertion: The array is inserted into the cortex using a pneumatic inserter that drives the array into the tissue at high speed, ensuring consistent penetration depth. Unlike Neuralink’s robotic insertion of individual threads, the Utah Array is inserted as a single rigid structure in a single impact.

Signal Quality: The Utah Array provides high-quality intracortical recordings, capturing action potentials (spikes) from individual neurons and local field potentials from neural populations within approximately 100-200 micrometers of each electrode tip. The signal quality has been sufficient to achieve landmark results in motor control, handwriting decoding, and speech synthesis through the BrainGate program.

Limitations: The primary limitation of the Utah Array is its percutaneous connection. The array connects to external electronics through a bundle of fine wires that pass through the skull via a pedestal connector cemented to the cranial bone. This percutaneous connector creates a chronic wound site that requires ongoing care and carries risks of infection. Additionally, the rigid silicon structure of the array can cause chronic tissue damage through micro-motion at the electrode-tissue interface, and the fixed electrode length does not accommodate variations in cortical thickness.

The BrainGate Program

The BrainGate clinical research program, using Blackrock’s Utah Array as its primary neural interface, has generated the foundational clinical evidence for the invasive BCI field:

First Human Implant (2004): Matthew Nagle became the first person to use an intracortical BCI for real-time computer control. Using a Utah Array implanted in motor cortex, Nagle demonstrated thought-controlled cursor movement, email access, and basic television control — proving that direct cortical BCIs could provide meaningful function to patients with severe paralysis.

Robotic Arm Control (2012): In a landmark demonstration, BrainGate participant Cathy Hutchinson used neural signals decoded from a Utah Array to control a robotic arm, picking up a coffee cup and bringing it to her lips to drink — the first time she had self-directed a limb movement in 15 years. This demonstration generated worldwide media coverage and accelerated investment in BCI technology.

Handwriting Decoding (2021): Stanford BrainGate researchers demonstrated that neural signals from a Utah Array in motor cortex could be decoded to reconstruct imagined handwriting at speeds approaching normal writing rates. The participant, paralyzed from the neck down, could type approximately 90 characters per minute by imagining writing letters — faster than many smartphone users.

Speech Decoding: The Stanford BrainGate team achieved landmark results in decoding speech intentions from motor cortex activity. Using deep learning algorithms trained on neural recordings during attempted speech, the team decoded spoken words at rates approaching natural conversation, demonstrating that the motor cortex contains rich information about speech production that can be extracted with sufficient electrode coverage and sophisticated AI decoding.

Scientific Contribution

The Utah Array’s contribution to neuroscience extends far beyond the BrainGate clinical program. Thousands of Utah Arrays have been deployed in research laboratories worldwide, generating fundamental knowledge about motor cortex computation, sensory processing, memory, attention, and consciousness. The array has been used in research on non-human primates, rodents, cats, and other species, as well as in human clinical studies.

Key scientific contributions enabled by the Utah Array include the discovery of population coding principles in motor cortex, the characterization of neural adaptation and learning during BCI use, the demonstration that cortical representations can be stably decoded over months to years, and the identification of neural signatures associated with cognitive states including attention, decision-making, and error detection.

Next-Generation Development

Blackrock is developing next-generation neural interfaces that address the limitations of the current Utah Array:

Wireless Systems: Development of wireless versions of the Utah Array that eliminate the percutaneous connector, reducing infection risk and improving patient comfort. Wireless Utah Arrays would compete more directly with Neuralink’s fully wireless N1 implant.

Flexible Arrays: Research into flexible electrode arrays that conform to the cortical surface, reducing micro-motion damage and potentially improving long-term recording stability.

Higher Channel Count: Development of arrays with more than 100 electrodes to improve signal coverage and enable more sophisticated neural decoding applications.

Chronic Biocompatibility: Materials research focused on improving the long-term biocompatibility of implanted electrodes, reducing gliosis (scar tissue formation) and electrode degradation over years of implantation.

Competitive Positioning

Blackrock’s competitive advantages include the longest clinical track record in intracortical BCI, established manufacturing capabilities for neural interface hardware, extensive relationships with the neuroscience research community, and the deep evidence base generated by decades of BrainGate studies. The company’s products are the standard tools in thousands of neuroscience laboratories.

Blackrock’s competitive disadvantages include the percutaneous connector (while Neuralink and Synchron are fully wireless), the relatively small electrode count compared to Neuralink’s 1,024 electrodes, the rigid silicon structure that can cause tissue damage, and the company’s smaller funding base compared to venture-backed competitors.

Within the $2.94 billion BCI market, Blackrock serves both the research market (providing tools to neuroscience laboratories) and the clinical market (providing hardware for BrainGate and other clinical programs). The research market provides a stable revenue base while the clinical market represents the growth opportunity.

Relationship to Consciousness Research

The Utah Array has contributed directly to consciousness research by enabling researchers to study how neural activity in specific brain regions relates to conscious perception, attention, and awareness. Recordings from Utah Arrays in visual cortex, prefrontal cortex, and parietal cortex have provided empirical data relevant to Global Workspace Theory and Integrated Information Theory, contributing to the scientific foundation for the consciousness indicators framework.

For competitive analysis, see our BCI Company Comparison, Invasive vs. Non-Invasive BCI Analysis, and BCI Market Dashboard.

The Transition from Research to Commercial

Blackrock Neurotech faces a pivotal strategic challenge: transitioning from a research tools company to a commercial medical device company. The Utah Array has been the gold standard for neuroscience research for decades, providing a stable revenue base from academic and clinical research customers. However, the commercial BCI market — where revenue growth lies — requires a different product profile: wireless operation, higher channel counts, long-term biocompatibility, and manufacturing at scale.

The company’s next-generation products are designed to address these requirements. Wireless Utah Array variants eliminate the percutaneous connector that is the technology’s most significant clinical limitation. Higher-channel-count arrays improve the spatial coverage needed for complex decoding tasks like speech restoration. And investments in manufacturing infrastructure target the production volumes needed for commercial deployment beyond individual research sites.

Intellectual Property and Data Assets

Beyond its hardware products, Blackrock Neurotech possesses two uniquely valuable assets. First, an extensive patent portfolio covering electrode design, signal processing, neural interface packaging, and implant manufacturing — IP developed over decades of research and development. Second, the largest published dataset of human intracortical neural recordings in the world, generated through decades of BrainGate studies. This data asset is invaluable for training neural decoding algorithms, developing foundation models for neural data, and validating new BCI approaches.

The data advantage is difficult for competitors to replicate. Neuralink has only three implanted patients, and Synchron has a small Australian and US cohort. Blackrock’s decades of BrainGate recordings provide a dataset orders of magnitude larger, giving the company and its academic partners a foundation model training advantage that could prove as strategically important as the hardware itself. As the $2.94 billion BCI market grows, the value of proprietary neural data assets will increase correspondingly.

For competitive analysis, see our BCI Company Comparison, Invasive vs. Non-Invasive BCI Analysis, and BCI Market Dashboard.

Blackrock Neurotech and the Research-to-Clinic Pipeline

Blackrock’s unique position as the hardware supplier for the majority of human intracortical BCI research gives it unparalleled insight into the scientific challenges of bringing neural interfaces from laboratory to clinic. The company has directly participated in or supplied hardware for virtually every major advance in intracortical BCI — from early demonstrations of cursor control through BrainGate to recent breakthroughs in high-speed speech decoding and handwriting recognition. This accumulated experience across hundreds of research studies and dozens of implanted patients represents institutional knowledge that cannot be replicated through funding or engineering talent alone. The company’s challenge is converting this research ecosystem leadership into commercial market leadership before better-funded competitors like Neuralink leverage their engineering resources and public visibility to capture the clinical market that Blackrock’s technology helped create. The BCI market’s transition from research to clinical deployment will test whether decades of scientific leadership can be translated into sustainable commercial advantage, or whether the market will be captured by newer entrants with fresh technology and deeper capital reserves. For investors evaluating the $2.94 billion BCI market, Blackrock’s strategic evolution from research supplier to commercial device company represents one of the most consequential competitive dynamics in the space.

Neural Data as a Strategic Asset in the Foundation Model Era

In the emerging era of foundation models for neural data, Blackrock Neurotech’s decades of human intracortical recordings represent a strategic asset whose value is compounding rapidly. Foundation models — large neural networks pre-trained on diverse datasets that can be fine-tuned for specific tasks — have transformed natural language processing and computer vision, and the same paradigm is beginning to emerge for neural data. A foundation model trained on Blackrock’s extensive corpus of human motor cortex, speech cortex, and sensory cortex recordings could provide powerful priors for neural decoding across applications and patients, dramatically reducing the calibration data required for new BCI users. Synchron’s Chiral project pursues a similar vision using endovascular recordings, but Blackrock’s intracortical data provides higher signal quality and richer neural representations. The company’s data advantage is difficult to replicate: accumulating equivalent datasets would require decades of human implant studies, and no competitor has the clinical trial history to match. As AI algorithms become the primary differentiator in BCI performance, the value of proprietary neural training data may ultimately exceed the value of the hardware itself within the $2.94 billion BCI market.

The Scientific Legacy and Its Commercial Value

Blackrock Neurotech’s scientific legacy represents an intangible asset with significant commercial value. The company’s hardware has been used in virtually every major advance in intracortical BCI research, from early cursor control demonstrations to recent breakthroughs in speech decoding and handwriting recognition. This scientific provenance provides credibility with regulatory agencies, clinical investigators, and institutional investors that newer competitors cannot match. The peer-reviewed evidence base generated using Blackrock hardware serves as the foundation of the scientific case for invasive BCI technology, demonstrating safety and efficacy across multiple applications and patient populations. For the BCI market’s transition from research to commercial deployment, this evidence base provides a regulatory and clinical foundation that competing platforms must build from scratch, giving Blackrock a strategic advantage that complements its hardware capabilities.

Updated March 2026. Contact info@subconsciousmind.ai for corrections or additional entity intelligence.